Blog
RSS FeedPosted by Michael Wonder on 15 Dec 2017
An open-source consensus-based approach to value assessment
15 December 2017 - Value Assessment? Yes, But How? ...
Posted by Michael Wonder on 11 Dec 2017
NHS advises GPs not to prescribe “low value” drugs
30 November 2017 - NHS England will issue guidance to GPs and commissioners to limit the prescribing of “low value” ...
Posted by Michael Wonder on 30 Nov 2017
Reducing the waste in the massive health care system
30 November 2017 - Lorica Health's CEO Paul Nicolarakis says the health analytics company is helping the industry and government ...
Posted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...
Posted by Michael Wonder on 14 Oct 2017
Nearly one-third of new drugs are no better than older drugs, and some are worse
6 October 2017 - A focus on expediting drug development. ...
Posted by Michael Wonder on 14 Oct 2017
EMA responds to BMJ article questioning benefits of recent cancer drug approvals
13 October 2017 - As more cancer drugs are approved and prices continue to rise, questions have circulated on whether ...
Posted by Michael Wonder on 11 Oct 2017
The future of drug pricing: value over volume
11 October 2017 - Doctors and hospitals are increasingly being paid not for the quantity of care they provide, but ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 05 Oct 2017
Cancer patients given new drugs that won’t help them
5 October 2017 - Most new cancer drugs are given to patients without any evidence that they extend or improve ...
Posted by Michael Wonder on 04 Oct 2017
Novartis seeks outcomes-based pricing in Japan for cancer drug
5 October 2017 - Swiss pharma's effort could spark broad changes in nation's pricing system. ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 13 Sep 2017
Drug companies tie costs to outcomes
12 September 2017 - But early signs show little evidence that the plans lower prices. ...
Posted by Michael Wonder on 09 Sep 2017
Should value frameworks take a ‘societal perspective’?
6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...
Posted by Michael Wonder on 09 Sep 2017
Can a new value framework help ease friction over orphan drug prices?
7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...
Posted by Michael Wonder on 04 Sep 2017
Statistical and clinical significance
4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...